Pharmacotherapy for trichotillomania

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2009, Pages

  Hoppe, Lara ^a   Ipser, Jonathan C ^b   Fineberg, Naomi ^c   Chamberlain, Samuel ^d   Stein, Dan J ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c QUEEN ELIZABETH II HOSPITAL   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BROMAZEPAM; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; DESIPRAMINE; ESCITALOPRAM; ETIRACETAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; HALOPERIDOL; IMIPRAMINE; LAMOTRIGINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIAGABINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

CELL HETEROGENEITY; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; HAMILTON SCALE; HUMAN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REVIEW; SENSITIVITY ANALYSIS; SENSORIMOTOR CORTEX; TREATMENT OUTCOME; TREATMENT RESPONSE; TRICHOTILLOMANIA;

EID: 70049117174     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007662     Document Type: Review

References (54)

1. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL.Association of funding and conclusions in randomized drug trials - A reflection of treatment effect or adverse events?. Journal of the American Medical Association 2003;290:921-928. (Pubitemid 37430464)
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III). 3rd Edition. Washington, DC: American Psychiatric Press, 1980.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R). 3rd Edition. Washington, DC: American Psychiatric Association, 1987.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: American Psychiatric Association, 2000.
5. Baker CB, Johnsrud MT, Crismon ML, Robert AR, Woods SW. Quantitative analysis of sponsorship bias in economic studies of antidepressants. British Journal of Psychiatry 2003;183:498-506.
6. Beck AT, Ward C, Mendelson M. Beck Depression Inventory (BDI). Arch Gen Psychiatry 1961;4:561-571.
7. Benkelfat C, Murphy DL, Zohar J, Hill JL, Grover G, Insel TR. Clomipramine in Obsessive-Compulsive Disorder: Further evidence for a serotonergic mechanism of action. Archives of General Psychiatry 1989;46:23-28. (Pubitemid 19038404)
8. Black DW, Blum N. Trichotillomania treated with Clomipramine and a topical steroid. American Journal of Psychiatry 1992;149(6):842-843.
9. Bohne A, Keuthen NJ, Tuschen-Caffier B, Wilhelm S. Cognitive Inhibition in Trichotillomania and Obsessive-Compulsive Disorder. Behaviour Research and Therapy 2005;43:923-942. (Pubitemid 40719613)
10. Chamberlain SR, Fineberg NA, Blackwell AD, Robbins TW, Sahakian BJ. Motor inhibition and cognitive flexibility in obsessive-compulsive disorder and trichotillomania.. Am J Psychiatry 2006;163(7):1282-1284 (Pubitemid 44464460)
11. Christenson GA, Pyle RL, Mitchell JE. Estimated lifetime prevalence of Trichotillomania in college students. Journal of Clinical Psychiatry 1991;52(10):415-417.
12. Christenson GA, Mackenzie TB, Mitchell JE. Characteristics of 60 adult chronic hair pullers. American Journal of Psychiatry 1991;148:365-370.
13. Christenson GA, Crow SJ, Mitchell JE, Mackenzie TB, Crosby RD. Fluvoxamine in the treatment of Trichotillomania. CNS Spectrums 1998;3(9):64-71.
14. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. Egger M, Davey SG, Altman DG (Editors). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd edition. BMJ Publication Group, 2001.
15. Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Statistics in medicine 2002;21:1575-1600. (Pubitemid 34746064)
16. Deeks JJ, Higgins JPT, Altman DG. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. In: Higgins JPT, Green S editor(s). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.. Chichester, UK: John Wiley & Sons, Ltd., 2008.
17. Dickersin K, Min YI, Meinert CL. Factors influencing the publication of research results: Follow-up of applications submitted to two substantial review boards. JAMA 1992;267(3):374-378
18. Diefenbach GJ, Tolin DF, Hannan S, Crocetto J, Worhunsky P. Trichotillomania: Impact on psychosocial functioning and quality of life. Behaviour and Research Therapy 2005;43:869-884. (Pubitemid 40719610)
19. Elbourne ER, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: Methodological issues. International Journal of Epidemiology 2002;31:140-149. (Pubitemid 34284916)
20. Epperson CN, Fasula D, Wasylink S, Price LH, McDougle CJ. Risperidone addition in serotonin reuptake inhibitor-resistant Trichotillomania: Three cases. Journal of Child and Adolescent Psychopharmacology 1999;9(1):43-49. (Pubitemid 29230952)
21. Gadde KM, Wagner RH (2nd), Connor KM, Foust MS. Escitalopram treatment of Trichotillomania. International Clinical Psychopharmacology 2007;22(1):39-42.
22. Grant JE, Odlaug BL, Potenza, MN. Addicted to hair pulling? How an alternate model of Trichotillomania may improve treatment outcome. Harvard Review of Psychiatry 2007;15:80-85.
23. Guy W. ECDEU assessment manual for psychopharmacology. Washington, DC: U.S. National Institute of Health, 1976.
24. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery & Psychiatry 1960;23:56-62.
25. Higgins JT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(6):557-560
26. Iancu I, Weizman A, Kindler S, Sasson Y, Zohar J. Serotonergic drugs in Trichotillomania. Journal of Nervous and Mental Disease 1996;184(10):641-644.
27. Keuthen NJ, Savage CR, O'Sullivan RL, Brown HD, Shera DM, Cyr D, Jenike MA, Baer L. Neuropsychological functioning in Trichotillomania. Biological Psychiatry 1996;39:747-749.
28. Keuthen NJ, Makris N, Schlerf JE, Martis B, Savage CR, McMullin K, Seidman LJ, Schmahmann JD, Kennedy DN, Hodge SM, Rauch S. Evidence for reduced cerebellar volumes in Trichotillomania. Biological Psychiatry 2007;61:374-381. (Pubitemid 46108690)
29. Koran LM, Ringold A, Hewlett W. Fluoxetine for Trichotillomania: An open clinical trial. Psychopharmacology Bulletin 1992;28(22):145-149.
30. Lochner C, Seedat S, Niehaus DJ, Stein DJ. Topiramate in the treatment of Trichotillomania: An open-label pilot study. International Clinical Psychopharmacology 2006;21(5):255-259. (Pubitemid 44162476)
31. McElroy SL, Hudson JI, Pope HG, Keck PE, Aizley HG. The DSM-III-R impulse control disorders not elsewhere classified: clinical characteristics and relationship to other psychiatric disorders. American Journal of Psychiatry 1992;149(3):318-327.
32. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979;134:382-389 (Pubitemid 9136500)
33. Ninan PT, Knight B, Kirk L, Rothbaum BO, Kelsey J, Nemeroff CB. A controlled trial of venlaflaxine in Trichotillomania: Interim phase I results. Psychopharmacology Bulletin 1998;34(2):221-224. (Pubitemid 28292712)
34. Pollard CA, Ibe IO, Krojanker DN, Kitchen AD, Bronson SS, Flynn TM. Clomipramine treatment of Trichotillomania: A follow-up report on four cases. Journal of Clinical Psychiatry 1991;52(3):128-130.
35. Rauch SL, Wright CI, Savage CR, Martis B, McMullin KG, Wedwig MM, Gold AL, Keuthen NJ. Brain activation during implicit sequence learning in individuals with Trichotillomania. Psychiatry Research: Neuroimaging 2007;154:233-240. (Pubitemid 46428521)
36. Rettew DC, Cheslow DL, Rapoport JL, Leonard HL, Lenane MC. Neuropsychological test performance in Trichotillomania: A further link with Obsessive-Compulsive Disorder. Journal of Anxiety Disorders 1991;5:225-235.
37. Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. International Journal of Epidemiology 2002;31:150-153. (Pubitemid 34284917)
38. Rothbaum BO, Shaw L, Morris R, Ninan PT. Prevalence of Trichotillomania in a college freshman population. Journal of Clinical Psychiatry 1993;54(2):72-73. (Pubitemid 23078216)
39. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. International Clinical Psychopharmacology 1996;11 Suppl 3:89-95.
40. Song F, Eastwood AJ, Gilbody S, Duley L, Sutton AJ. Publication and related biases. Health Technol Assess 2000;4:1-115.
41. Spitzer R, Williams J, Gibbons M. Instructional manual for the structured clinical interview for DSM-IV.. New York: New York State Psychiatric Institute., 1996.
42. Stanley MA, Bowers TC, Swann AC, Taylor DJ. Treatment of Trichotillomania with Fluoxetine. Journal of Clinical Psychiatry 1991;52(6):282.
43. Stanley MA, Hannay HJ, Breckenridge JK. The neuropsychology of Trichotillomania. Journal of Anxiety Disorders 1997;11(5):473-488.
44. Stein DJ, van Heerden B, Hugo C, van Kradenburg J, Warwick J, Zungu-Dirwayi N, Seedat, S. Functional brain imaging and pharmacotherapy in Trichotillomania single photon emission computed tomography before and after treatment with the selective serotonin reuptake inhibitor citalopram. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2002;26:885-890. (Pubitemid 35245554)
45. Stewart RS, Nejtek VA. An open-label, flexible dose study of olanzapine in the treatment of Trichotillomania. Journal of Clinical Psychiatry 2003;64(1):49-52. (Pubitemid 36182229)
46. Swedo SE, Rapoport JL, Leonard HL, Schapiro MB, Rapoport SI, Grady CL. Regional cerebral glucose metabolism of women with Trichotillomania. Arch Gen Psychiatry 1991;48(9):828-833.
47. Swedo SE, Leonard HL. Trichotillomania: An Obsessive Compulsive Spectrum Disorder?. Psychiatric Clinics of North America 1992;15(4):777-790. (Pubitemid 23032174)
48. SRS 4.0. http://www.trialstat.com.
49. Van Ameringen M, Mancini C, Oakman JM, Farvolden P. The potential role of haloperidol in the treatment of Trichotillomania. Journal of Affective Disorders 1999;56:219-226. (Pubitemid 30058226)
50. Van Minnen A, Hoogduin KAL, Keijsers GPJ, Hellenbrand I, Hendriks GJ. Treatment of Trichotillomania with behavioral therapy or Fluoxetine. Archives of General Psychiatry 2003;60:517-522.
51. Verbeke M, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York: Springer, 2000.
52. World Health Organization. International statistical classification of diseases and health related problems. World Health Organization. Tenth revision. Vol. 1, Geneva: World Health Organization, 1992.
53. Winchel RM, Jones JS, Stanley B, Molcho A, Stanley M. Clinical characteristics of Trichotillomania and its reponse to fluoxetine. Journal of Clinical Psychiatry 1992;53(9):304-308.
54. Woods DW, Flessner CA, Franklin ME, Keuthen NJ, Goodwin RD, Stein DJ, Walther MR, Trichotillomania Learning Center Advisory Board. The Trichotillomania Impact Project (TIP): Exploring phenomenology, functional impairment, and treatment utilization. Journal of Clinical Psychiatry 2006;67:1877-1888.